Overview
Wenling Tu practices practicing medicine in Chengdu, China.
Their clinical expertise encompasses Papillary Thyroid Cancer, Thyroid Cancer, Graves Disease, and Hyperthyroidism.
They are actively involved in clinical research, co-authoring 37 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Wenling Tu
Is Wenling Tu a top-rated expert for Papillary Thyroid Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Wenling Tu is classified as an Experienced expert for Papillary Thyroid Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Wenling Tu participate in research or clinical trials?
Yes. Wenling Tu has published 37 articles and abstracts on conditions like Papillary Thyroid Cancer. You can view a list of Wenling Tu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Graves DiseaseTu isExperienced. Learn about Graves Disease.
- HyperthyroidismTu isExperienced. Learn about Hyperthyroidism.
- Lung CancerTu isExperienced. Learn about Lung Cancer.
- Papillary Thyroid Cancer
- Thyroid CancerTu isExperienced. Learn about Thyroid Cancer.